RGEN

Repligen Corp. 10-Q Summary: Period Ended December 31, 1998

Business Context and Reporting Period

This is a Quarterly Report (Form 10-Q) for Repligen Corporation for the three and nine months ended December 31, 1998. Repligen is a biopharmaceutical company developing drugs for cancer, organ transplantation, and autoimmune diseases. Its primary commercial products involve affinity chromatography materials (recombinant Protein A) used in the production of therapeutic monoclonal antibodies. The company also maintains a proprietary drug discovery program, most notably for CTLA4-Ig.

Key Financial Metrics

Revenue Breakdown (9 Months): Research & Development ($1,013,675), Product Sales ($674,871), Investment Income ($169,912), Other ($85,274).

Expense Breakdown (9 Months): R&D Expenses ($1,352,648), SG&A ($1,029,013), Cost of Products Sold ($429,801).

Material Changes vs. Prior Period

• Revenue Decline (Quarterly): Total revenues decreased 22% ($164,000) compared to the prior year quarter. This was driven by a 27% drop in R&D revenue (due to the absence of a milestone payment from Pfizer Inc. received in the prior year) and a 21% drop in product sales.
• Revenue Stability (Year-to-Date): Total revenues increased slightly by 1% ($11,000) compared to the prior year-to-date period.
• Expense Increases: Total expenses increased 8% for the quarter and 17% for the nine-month period. R&D expenses rose 27% year-to-date due to increased staffing for proprietary drug discovery. SG&A expenses rose 12% due to patent costs and shareholder services.
• Liquidity: Cash and cash equivalents decreased by approximately $1.03 million from the beginning of the fiscal year, primarily due to net operating losses and capital expenditures.
• Product Margins: Cost of products sold as a percentage of product revenue increased to 64% for the nine-month period (from 50% in the prior year), attributed to increased inventory reserves for new Protein A products.

Guidance, Outlook, and Material Events

• Strategic Agreement: On December 17, 1998, Repligen entered into a ten-year agreement with Amersham Pharmacia Biotech (APB) to become the preferred manufacturer of APB's recombinant Protein A. APB agreed to pay an initial transfer fee and purchase manufactured product. Specific pricing and volume terms were redacted for confidential treatment.
• Liquidity Outlook: Management believes current cash equivalents and marketable securities are sufficient to meet working capital and capital expenditure requirements for the next 24 months, despite anticipated increases in operating costs.
• Legal Proceedings: Repligen is engaged in litigation against Bristol-Myers Squibb (BMS) regarding patents for CTLA4-Ig. Repligen seeks to correct inventorship on BMS patents to secure shared rights. Failure in this litigation could restrict commercialization of CTLA4-Ig.
• Year 2000 Compliance: The company believes the Year 2000 problem does not pose significant operational risks and expects full compliance by the end of 1999 without material financial impact.

Investor Verification Checklist

• Revenue Sustainability: Verify the impact of the loss of the Pfizer milestone payment on future R&D revenue projections.
• APB Agreement Terms: Confirm the specific volume commitments and pricing schedules in the Amersham Pharmacia Biotech agreement, as these were redacted in the public filing.
• Product Margin Trends: Monitor the cost of goods sold ratio for Protein A products to ensure inventory reserves do not continue to erode margins.
• Legal Risk: Assess the potential outcome of the patent litigation with Bristol-Myers Squibb and its impact on the CTLA4-Ig pipeline.
• Cash Burn Rate: Track the rate of cash consumption against the stated 24-month runway to determine if additional financing will be required sooner than anticipated.